Day One Biopharmaceuticals Inc (NASDAQ: DAWN) on Tuesday, soared 7.03% from the previous trading day, before settling in for the closing price of $6.97. Within the past 52 weeks, DAWN’s price has moved between $5.64 and $16.76.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales slid by -38.09% over the last five years. The company achieved an average annual earnings per share of -21.68%. With a float of $74.64 million, this company’s outstanding shares have now reached $102.43 million.
Day One Biopharmaceuticals Inc (DAWN) Insider Activity
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Day One Biopharmaceuticals Inc is 27.13%, while institutional ownership is 74.52%. The most recent insider transaction that took place on Aug 18 ’25, was worth 27,786. In this transaction COO and CFO of this company sold 4,106 shares at a rate of $6.77, taking the stock ownership to the 278,000 shares. Before that another transaction happened on Aug 18 ’25, when Company’s Gen Counsel & Secretary sold 4,365 for $6.77, making the entire transaction worth $29,538. This insider now owns 54,858 shares in total.
Day One Biopharmaceuticals Inc (DAWN) Earnings and Forecasts
As on 9/30/2024, Multinational firm has announced its last quarter scores, in which it reported 0.38 earnings per share (EPS) for the period topping the consensus outlook (set at -0.25) by 0.63. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.31 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -21.68% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 57.50% during the next five years compared to -38.09% drop over the previous five years of trading.
Day One Biopharmaceuticals Inc (NASDAQ: DAWN) Trading Performance Indicators
Day One Biopharmaceuticals Inc (DAWN) is currently performing well based on its current performance indicators. A quick ratio of 9.53 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 4.07.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.91, a number that is poised to hit -0.29 in the next quarter and is forecasted to reach -0.79 in one year’s time.
Technical Analysis of Day One Biopharmaceuticals Inc (DAWN)
Analysing the last 5-days average volume posted by the [Day One Biopharmaceuticals Inc, DAWN], we can find that recorded value of 1.06 million was lower than the volume posted last year of 1.38 million. As of the previous 9 days, the stock’s Stochastic %D was 81.47%.
During the past 100 days, Day One Biopharmaceuticals Inc’s (DAWN) raw stochastic average was set at 74.34%, which indicates a significant decrease from 98.79% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.32 in the past 14 days, which was lower than the 0.36 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $6.65, while its 200-day Moving Average is $9.29. Now, the first resistance to watch is $7.65. This is followed by the second major resistance level at $7.84. The third major resistance level sits at $8.20. If the price goes on to break the first support level at $7.10, it is likely to go to the next support level at $6.74. Should the price break the second support level, the third support level stands at $6.56.
Day One Biopharmaceuticals Inc (NASDAQ: DAWN) Key Stats
Market capitalization of the company is 764.14 million based on 102,432K outstanding shares. Right now, sales total 131,160 K and income totals -95,500 K. The company made 33,910 K in profit during its latest quarter, and -30,320 K in sales during its previous quarter.
